RxDoctor Payments Data

Gary Graham, MD

Family Medicine · Roosevelt, UTNPI 1811910359

Payments from drug & device makers

$1,274in general payments, 2019–2025

Across 86 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$254
  • Teva Pharmaceuticals USA, Inc.$212
  • Novo Nordisk$147
  • Lilly USA, LLC$110
  • AstraZeneca$101
  • Dexcom, Inc.$74
  • plus $377 from 12 others

What the payments were for

  • Food & beverage$1,274100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,274 in reported general payments places this provider in the 60th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$45,310
Medicare patients
169
Services billed
461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$47,219
OzempicSemaglutide43$43,341
JardianceEmpagliflozin16$18,151
MounjaroTirzepatide12$12,982
TrulicityDulaglutide13$12,780
XareltoRivaroxaban15$11,878
EntrestoSacubitril/Valsartan24$8,167
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,918
MyrbetriqMirabegron17$7,483
FarxigaDapagliflozin Propanediol15$4,197
SymbicortBudesonide/Formoterol Fumarate15$3,337
Humalog Kwikpen U-100Insulin Lispro11$2,726
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,709
Omeprazole105$2,170
Nebivolol Hcl24$1,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$47,21990 claims
Novo NordiskOzempic$147$43,34143 claims
Lilly USA, LLCMounjaro, Trulicity$110$25,76225 claims
NovartisEntresto$40$8,16724 claims
GSKTrelegy Ellipta$30$7,91812 claims
AstraZenecaFarxiga, Symbicort$101$7,53430 claims
Astellas Pharma US IncMyrbetriq$33$7,48317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 928 family medicine providers in Utah.

Other family medicine in Roosevelt

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →